Oncology Central

Cyramza® meets primary endpoint of overall survival in liver cancer study

It has been reported that Cyramza® (ramucirumab) has met its primary endpoint of overall survival, as well as its secondary goal of progression-free survival in late-stage liver cancer study.
To view restricted content, please:



News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.